These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 33743356)
1. Design and synthesis of novel (S)-Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. Han Mİ; Atalay P; Tunç CÜ; Ünal G; Dayan S; Aydın Ö; Küçükgüzel ŞG Bioorg Med Chem; 2021 May; 37():116097. PubMed ID: 33743356 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxen. Han MI; Bekçi H; Uba AI; Yıldırım Y; Karasulu E; Cumaoğlu A; Karasulu HY; Yelekçi K; Yılmaz Ö; Küçükgüzel ŞG Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800365. PubMed ID: 31115928 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives. Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors. Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863 [TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of Tolmetin Hydrazide-Hydrazones and Discovery of a Potent Apoptosis Inducer in Colon Cancer Cells. Küçükgüzel ŞG; Koç D; Çıkla-Süzgün P; Özsavcı D; Bingöl-Özakpınar Ö; Mega-Tiber P; Orun O; Erzincan P; Sağ-Erdem S; Şahin F Arch Pharm (Weinheim); 2015 Oct; 348(10):730-42. PubMed ID: 26287512 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines. Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828 [TBL] [Abstract][Full Text] [Related]
10. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
11. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities, Alam MS; Lee DU Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors. Şenkardeş S; Han Mİ; Kulabaş N; Abbak M; Çevik Ö; Küçükgüzel İ; Küçükgüzel ŞG Mol Divers; 2020 Aug; 24(3):673-689. PubMed ID: 31302853 [TBL] [Abstract][Full Text] [Related]
15. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586 [TBL] [Abstract][Full Text] [Related]
16. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
19. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
20. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents. Labib MB; Philoppes JN; Lamie PF; Ahmed ER Bioorg Chem; 2018 Feb; 76():67-80. PubMed ID: 29153588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]